Halda Therapeutics
Kat Kayser-Bricker has a diverse work experience in the fields of scientific research and pharmaceuticals. Kat currently serves as the Chief Scientific Officer at Halda Therapeutics since March 2021. Prior to this role, they were the Senior Director and Head of Portfolio Strategy at the same company from August 2020 to March 2021. Before joining Halda Therapeutics, they worked as a Director at the company from May 2019 to August 2020.
In addition to their roles at Halda Therapeutics, Kayser-Bricker holds a position as a Board Member at Humanity Talent Network since September 2022.
Earlier in their career, they held senior positions at FORMA Therapeutics, Inc. starting from 2009. Kat served as the Director and Head of Early Discovery Chemistry from March 2018 to May 2019, and as the Principal Scientist and Head of Automated Synthesis from February 2009 to February 2018.
Kayser-Bricker began their professional journey as a Postdoctoral Associate at Yale University from July 2007 to January 2009. During this time, they conducted research in synthetic methodology and natural product synthesis, developing peptide-based asymmetric phosphorylation and phosphoramidite transfer catalysts. Kat also contributed to the enantioselective total syntheses of PI5P-DiC8, its enantiomer, and myo-Inositol-6-Phosphate.
Overall, Kayser-Bricker's work experience reflects a strong background in scientific research and leadership roles in the pharmaceutical industry.
Kat Kayser-Bricker earned a Bachelor of Science degree in Chemistry from the University of Maryland, where they studied from 1998 to 2002. Kat then pursued further education at Yale University, where they obtained their PhD in Chemistry from 2002 to 2007.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.